# Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

> **NCT05162131** · PHASE1 · TERMINATED · sponsor: **SFJ Pharmaceuticals, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Bentracimab (PB2452) 100 mg or Placebo
- **DRUG:** Bentracimab (PB2452) 300 mg or Placebo
- **DRUG:** Bentracimab (PB2452) 1000 mg or Placebo
- **DRUG:** Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)
- **DRUG:** Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)
- **DRUG:** Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)
- **DRUG:** Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)

## Key facts

- **NCT ID:** NCT05162131
- **Lead sponsor:** SFJ Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-25
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** After recruitment of Cohorts 1-4 was completed, Sponsor decided to terminate study, initially due to COVID and then considering that PK data from the dose planned to be tested in Cohort 5 (18000 mg) would be available from the ongoing Phase 3 study.
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162131, "Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05162131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*